---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000050"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-15T00:24:40.492582+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health appoints Torsten Hombeck as CFO, effective June 15, 2023

## Summary
- Torsten Hombeck, Ph.D., named CFO; previously CFO of Akari Therapeutics.
- Annual base salary of $325,000 with bonus eligibility up to 50% of base.
- Initial stock option grant of 13,333 shares, vesting 33.3% annually over 3 years.
- Severance: 6 months base salary and COBRA if terminated without cause or resigns for good reason.
- Subject to 12-month non-compete and non-solicitation covenants.

## SEC filing metadata
- accession: 0000926617-23-000050
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000050/0000926617-23-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000050/awh-20230516x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000050
- JSON: https://secwatch.observer/filing/0000926617-23-000050.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000050.txt

## Key facts
- Executive change
  Torsten Hombeck was appointed as Chief Financial Officer at Aspira Women's Health Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: appointed Tortsten Hombeck, Ph.D. as the Company’s Chief Financial Officer, effective as of June 15, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000050/0000926617-23-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.